Variation in vaccine response in normal populations

Pharmacogenomics

Volumn 5, Issue 4, 2004, Pages 417-427

  Ovsyannikova, Inna G ^a   Jacobson, Robert M ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antibody level; Antigen processing; HLA class I; HLA DM; II and III genes; Peptides; Polymorphisms; TAP; Vaccine response; Variation in immune response

Indexed keywords

BCG VACCINE; CARRIER PROTEIN; DIPHTHERIA VACCINE; DNA VACCINE; HEPATITIS B VACCINE; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DM ANTIGEN; IMMUNOLOGICAL ADJUVANT; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; ORAL POLIOMYELITIS VACCINE; PEPTIDE; PERTUSSIS VACCINE; TETANUS TOXOID; VIRUS VACCINE;

ALLELE; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; DRUG DESIGN; DRUG RESPONSE; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS B; HEPATITIS C; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENETICS; INFLUENZA; MEASLES; PHARMACOGENETICS; PHARMACOGENOMICS; REVIEW; WART VIRUS;

HUMANS; NORMAL DISTRIBUTION; POLYMORPHISM, GENETIC; VACCINATION; VACCINES; VARIATION (GENETICS);

PAPILLOMAVIRUS;

EID: 3142745352     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.5.4.417     Document Type: Review

References (102)

1. Poland GA, Jacobson RM, Thampy AM et al.: Measles reimmunization in children seronegative after initial immunization. JAMA 277, 1156-1158 (1997).
2. Mathias RG, Meekison WG, Arcand TA, Schechter MT: The role of secondary vaccine failures in measles outbreaks. Am. J. Public Health 79, 475-478 (1989).
3. Boulianne N, De Serres G, Ratnam S, Ward BJ, Joly JR, Duval B: Measles, mumps, and rubella antibodies in children 5-6 years after immunization: effect of vaccine type and age at vaccination. Vaccine 13, 1611-1616 (1995).
4. Ammari LK, Bell LM, Hodinka RL: Secondary measles vaccine failure in healthcare workers exposed to infected patients. Infect. Control Hosp. Epidemiol. 14, 81-86 (1993).
5. Reyes MA, de Borrero MF, Roa J, Bergonzoli G, Saravia NG: Measles vaccine failure after documented seroconversion. Pediatr. Infect. Dis. J. 6, 848-851 (1987).
6. Anders JF, Jacobson RM, Poland GA, Jacobsen SJ, Wollan PC: Secondary failure rates of measles vaccines: a meta-analysis of published studies. Pediatr. Infect. Dis. J. 15, 62-66 (1996).
7. Esser MT, Marchese RD, Kierstead LS et al.: Memory T cells and vaccines. Vaccine 21, 419-430 (2003).
8. Gans H, Yasukawa L, Rinki M et al.: Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J. Infect. Dis. 184, 817-826 (2001).
9. Pabst HF, Spady DW, Carson MM, Krezolek MP, Barreto L, Wittes RC: Cell-mediated and antibody immune responses to AIK-C and Connaught monovalent measles vaccine given to 6 month old infants. Vaccine 17, 1910-1918 (1999).
10. Stirnadel HA, Al Yaman F, Genton B, Alpers MP, Smith TA: Assessment of different sources of variation in the antibody responses to specific malaria antigens in children in Papua New Guinea. Int. J. Epidemiol. 29, 579-586 (2000).
11. Pabst HF, Spady DW: Effect of breast-feeding on antibody response to conjugate vaccine. Lancet 336, 269-270 (1990).
12. Christy C, Pichichero ME, Reed GF et al.: Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines. Pediatrics 96, 584-587 (1995).
13. Greenberg DP, Vadheim CM, Partridge S, Chang SJ, Chiu CY, Ward JI: Immunogenicity of Haemophilus influenzae type B tetanus toxoid conjugate vaccine in young infants. J. Infect. Dis. 170, 76-81 (1994).
14. McMahon BJ, Williams J, Bulkow L et al.: Immunogenicity of an inactivated hepatitis A vaccine in Alaska native children and native and non-native adults. J. Infect. Dis. 171, 676-679 (1995).
15. Poland GA, Jacobson RM, Colbourne SA et al.: Measles antibody seroprevalence rates among immunized Inuit, Innu and Caucasian subjects. Vaccine 17, 1525-1531 (1999).
16. Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ: Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 21, 4604-4608 (2003).
17. Feinstein AR: Clinical judgment in the era of automation. Ann. Otol. Rhinol. Laryngol. 79, 728-737 (1970).
18. Feinstein AR: 'Clinical Judgment' revisited: the distraction of quantitative models. Ann. Intern. Med. 120, 799-805 (1994).
19. Chen RT, Markowitz LE, Albrecht P et al.: Measles antibody: reevaluation of protective titers. J. Infect. Dis. 162, 1036-1042 (1990).
20. Samb B, Aaby P, Whittle HC et al.: Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr. Infect. Dis. J. 14, 203-209 (1995).
21. Plotkin SA: Immunologic correlates of protection induced by vaccination. Pediatr. Infect. Dis. J. 20, 63-75 (2001).
22. Orenstein WA, Albrecht P, Herrmann KL, Bernier R, Bart KJ, Rovira EZ: The plaque-neutralization test as a measure of prior exposure to measles virus. J. Infect. Dis. 155, 146-149 (1987).
23. Poland GA, Jacobson RM: The genetic basis for variation in antibody response to vaccines. Curr. Opin. Pediatr. 10, 208-215 (1998).
24. Tan P-L, Jacobson RM, Poland GA, Jacobsen SJ, Pankratz SV: Twin studies of immunogenicity - determining the genetic contribution to vaccine failure. Vaccine 19, 2434-2439 (2001).
25. Griffin DE: Immune responses during measles virus infection. Curr. Top. Microbiol. Immunol. 191, 117-134 (1995).
26. So A: Genetics, polymorphism and regulation of expression of HLA region genes. In: HLA and Disease. Lechler R (Ed.), Academic Press, San Diego, CA, USA 1-29 (1994).
27. Townsend A, Trowsdale J: The transporters associated with antigen presentation. Semin. Cell Biol. 4, 53-61 (1993).
28. Spies T, DeMars R: Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter. Nature 351, 323-324 (1991).
29. Suh W-K, Cohen-Doyle MF, Fruh K, Wang K, Peterson PA, Williams DB: Interaction of MHC class I molecules with the transporter associated with antigen processing. Science 264, 1322-1326 (1994).
30. Trowsdale J, Hanson I, Mockridge I, Beck S, Townsend A, Kelly A: Sequences encoded in the class II region of MHC related to the 'ABC' superfamily of transporters. Nature 348, 741-744 (1990).
31. Deverson EV, Gow IR, Coadwell J, Monaco JJ, Butcher GW, Howard JC: MHC class II region encoding proteins related to the multidrug resistance family of transmembrane transporters. Nature 348, 738-741 (1990).
32. Spies T, Bresnahan M, Bahram S et al.: A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 348, 744-747 (1990).
33. Brusic V, van Endert P, Zeleznikow J, Daniel S, Hammer J, Petrovsky N: A neural network model approach to the study of human TAP transporter. In Silico Biol. 1(2), 109-121 (1999).
34. Monaco JJ: Pathways for the processing and presentation of antigens to T cells. J. Leukoc. Biol. 57, 543-547 (1995).
35. Long EO, Jacobson S: Pathways of viral antigen processing and presentation to CTL: defined by the mode of virus entry? Immunol. Today 10, 45-48 (1989).
36. Jackson MR, Peterson PA: Assembly and intracellular transport of MHC class I molecules. Ann. Rev. Cell Biol. 9, 207-235 (1993).
37. Dawson DV, Ozgur M, Sari K, Ghanayem M, Kostyu DD: Ramifications of HLA class I polymorphism and population genetics for vaccine development. Genet. Epidemiol. 20, 87-106 (2001).
38. Szafer F, Oksenberg JR, Steinman L: New allelic polymorphisms in TAP genes. Immunogenetics 39, 374 (1994).
39. Powis SH, Tonks S, Mockridge I, Kelly AP, Bodmer JG, Trowsdale J: Alleles and haplotypes of the MHC-encoded ABC transporters TAP1 and TAP2. Immunogenetics 37, 373-380 (1993).
40. Aoki Y, Isselbacher KJ, Pillai S: Polymorphisms involving the transmembrane domains of human TAP2. Immunogenetics 38, 382 (1993).
41. Malnati MS, Marti M, LaVaute T et al.: Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells. Nature 357, 702-704 (1992).
42. Malnati MS, Ceman S, Weston M, DeMars R, Long EO: Presentation of cytosolic antigen by HLA-DR requires a function encoded in the class II region of the MHC. J. Immunol. 151, 6751-6756 (1993).
43. Nuchtern JG, Biddison WE, Klausner RD: Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature 343, 74-76 (1990).
44. + T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway. J. Exp. Med. 194, 1053-1068 (2001).
45. Lautscham G, Rickinson A, Blake N: TAP-independent antigen presentation on MHC class I molecules: lessons from Epstein-Barr virus. Microbes Infect. 5, 291-299 (2003).
46. Neumeister C, Nanan R, Cornu TI et al.: Measles virus and canine distemper virus target proteins into a TAP-independent MHC class I-restricted antigen-processing pathway. J. Gen. Virol. 82, 441-447 (2001).
47. Carrington M, Colonna M, Spies T, Stephens JC, Mann DL: Haplotypic variation of the transporter associated with antigen processing (TAP) genes and their extension of HLA class II region haplotypes. Immunogenetics 37, 266-273 (1993).
48. van Endert PM, Lopez MT, Patel SD, Monaco JJ, McDevitt HO: Genomic polymorphism, recombination, and linkage disequilibrium in human major histocompatibility complex-encoded antigen-processing genes. Proc. Natl. Acad. Sci. USA 89, 11594-11597 (1992).
49. Hill A, Ploegh H: Getting the inside out: the transporter associated with antigen processing (TAP) and the presentation of viral antigen. Proc. Natl. Acad. Sci. USA 92, 341-343 (1995).
50. Neefjes JJ, Momburg F, Hämmerling GJ: Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 261, 769-771 (1993).
51. Shepherd JC, Schumacher TNM, Ashton-Rickardt PG et al.: TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective. Cell 74, 577-584 (1993).
52. Barron KS, Reveille JD, Carrington M, Mann DL, Robinson MA: Susceptibility to Reiter's syndrome is associated with alleles of TAP genes. Arthritis Rheum. 38, 684-689 (1995).
53. Savage DA, Ng SC, Howe HS, Ngai JLF, Darke C, Hui KM: HLA and TAP associations in Chinese systemic lupus crythematosus patients. Tissue Antigens 46, 213-216 (1995).
54. Momburg F, Roelse J, Howard JC, Butcher GW, Hämmerling GJ, Neefjes JJ: Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature 367, 648-651 (1995).
55. Heemels M-T, Ploegh HL: Substrate specificity of allelic variants of the TAP peptide transporter. Immunity 1, 775-784 (1994).
56. Daniel S, Brusic V, Caillat-Zucman S et al.: Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules. J. Immunol. 161, 617-624 (1998).
57. Newport MJ, Goetghebuer T, Weiss HA et al: Genetic regulation of immune responses to vaccines in early life. Genes Immun. 5, 122-129 (2004).
58. Ovsyannikova IG, Jacobson RM, Vierkant RA, Schaid DJ, Jacobsen SJ, Poland GA: The role of HLA genes in measles vaccine virus (MVV) antibody (Ab) hyper-response. Fifth Annual Conference on Vaccine Research, Baltimore, MD, USA S31 (2002) (Abstract).
59. Ovsyannikova IG, Jacobson RM, Vierkant RA, Pankratz SV, Jacobsen SJ, Poland GA: Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Vaccine 22(15-16), 1914-1920 (2004).
60. Jacobson RM, Poland GA, Vierkant RA et al.: The association of class I HLA alleles and antibody levels following a single dose of measles vaccine. Hum. Immunol. 64, 103-109 (2003).
61. Poland GA, Ovsyannikova IG, Jacobson RM et al.: Identification of an association between HLA class II alleles and low antibody levels after measles immunization. Vaccine 20, 430-438 (2001).
62. Ovsyannikova IG, Rabe DE, Sohni Y et al.: HLA-DPA1 alleles and measles vaccine antibody (Ab) response: Preliminary results. First Annual Conference on Vaccine Research, Washington, D.C. 23 (1998) (Abstract).
63. St. Sauver JL, Ovsyannikova IG, Jacobson RM et al.: Associations between human leukocyte antigen homozygosity and antibody levels to measles vaccine. J. Infect. Dis. 185, 1545-1549 (2002).
64. Dhiman N, Ovsyannikova IG, Pinsky NA et al.: Lack of association between transporter associated with antigen processing (TAP) and HLA-DM gene polymorphisms and antibody levels following measles vaccination. Eur. J. Immunogen. 30, 195-200 (2003).
65. Hayney MS, Poland GA, Dimanlig P, Schaid DJ, Jacobson RM, Lipsky JJ: Polymorphisms of the TAP2 gene may influence antibody response to live measles vaccine virus. Vaccine 15, 3-6 (1997).
66. Fling SP, Arp B, Pious D: HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells. Nature 368, 554-558 (1994).
67. Tiwari JL, Terasaki PI: HLA and Disease Associations. Springer-Verlag, New York (1985).
68. Bodmer J: World distribution of HLA alleles and implications for disease. Ciba Found. Symp. 197, 233-258 (1996).
69. Singh N, Agrawal S, Rastogi AK: Infectious diseases and immunity: special reference to major histocompatibility complex. Emerg. Infect. Dis. 3, 41-48 (1997).
70. de Jong MM, Nolte IM, de Vries EGE et al.: The HLA class III subregion is responsible for an increased breast cancer risk. Hum. Mol. Genet. 12, 2311-2319 (2003).
71. Singal DP, Li J, Zhu Y: HLA class III region and susceptibility to rheumatoid arthritis. Clin. Exp. Rheumatol. 18, 485-491 (2000).
72. Kruskall MS, Alper CA, Awdeh Z, Yunis EJ, Marcus-Bagley D: The immune response to hepatitis B vaccine in humans: inheritance patterns in families. J. Exp. Med. 175, 495-502 (1992).
73. Deulofeut H, Iglesias A, Mikael N et al.: Cellular recognition and HLA restriction of a midsequence HBsAg peptide in hepatitis B vaccinated individuals. Mol. Immunol. 30, 941-948 (1993).
74. Yap I, Chan SH: A new pre-S containing recombinant hepatitis B vaccine and its effect on non-responders: a preliminary observation. Ann. Acad. Med. Singapore 25, 120-122 (1996).
75. Vingerhoets J, Goilav C, Vanham G et al.: Non-response to a recombinant pre-S2-containing hepatitis B vaccine: association with the HLA-system. Ann. Soc. Belg. Med. Trop. 75, 125-129 (1995).
76. Stachowski J, Kramer J, Fust G, Maciejewski J, Baldmus CA, Petrányi GG: Relationship between the reactivity to hepatitis B virus vaccination and the frequency of MHC class I, II and III alleles in haemodialysis patients. Scand. J. Immunol. 42, 60-65 (1995).
77. Davenport MP, Quinn CL, Chicz RM et al.: Naturally processed peptides from two disease-resistance-associated HLA-DR13 alleles show related sequence motifs and the effects of the dimorphism at position 86 of the HLA-DRβ chain. Proc. Natl. Acad. Sci. USA 92, 6567-6571 (1995).
78. Craven DE, Awdeh ZL, Kunches LM et al.: Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic tyings. Ann. Intern. Med. 105, 356-360 (1986).
79. Alper CA, Kruskall MS, Marcus-Bagley D et al.: Genetic prediction of nonresponse to hepatitis B vaccine. N. Engl. J. Med. 321, 708-712 (1989).
80. Gelder CM, Lambkin R, Hart KW et al.: Associations bewtween human leukocyte antigens and nonresponsiveness to influenza vaccine. J. Infect. Dis. 185, 114-117 (2002).
81. Vejbaesya S, Songsivilai S, Tanwandee T, Rachaibun S, Chantangpol R, Dharakul T: HLA association with hepatitis C virus infection. Hum. Immunol. 61, 348-353 (2000).
82. Czaja AJ, Carpenter H, Santrach PJ, Moore SB: DR human leukocyte antigens and disease severity in chronic hepatitis C. J. Hepatol. 24, 666-673 (1996).
83. Constantini PK, Wawrzynowicz-Syczewska M, Clare M et al.: Interleukin-1, interleukin-10 and tumour necrosis factor-α gene polymorphisms in hepatitis C virus infection: an investigation of the relationships with spontaneous viral clearance and response to α-interferon therapy. Liver 22, 404-412 (2002).
84. Isaguliants MG, Ozeretskovskaya NN: Host background factors contributing to hepatitis C virus clearance. Curr. Pharm. Biotechnol. 4, 185-193 (2003).
85. Ellis JRM, Keating PJ, Baird J et al.: The association of an HPV16 oncogene variant with HIA-B7 has implications for vaccine design in cervical cancer. Nat. Med. 1, 464-470 (1995).
86. Apple RJ, Becker TM, Wheeler CM, Erlich HA: Comparison of human leukocyte antigen DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma. J. Natl. Cancer Inst. 87, 427-436 (1995).
87. Madeleine MM, Brumback B, Cushing-Haugen KL et al.: Human leukocyte antigen class II and cervical cancer risk: A population-based study. J. Infect. Dis. 186, 1565-1574 (2002).
88. Gostout BS, Poland GA, Calhoun ES et al.: TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol. Oncol. 88, 326-332 (2003).
89. Tindle RW: Human papillomavirus vaccines for cervical cancer. Curr. Opin. Immunol. 8, 643-650 (1996).
90. Poland GA, Hagensee ME, Koutsky LA et al.: A randomized double-blind, placebo-controlled trial of the immunogenicity and reactogenicity of a novel HPV 16 vaccine: Preliminary results. 18th International Papillomavirus Conference, HPV Clinical Workshop, Barcelona, Spain 363 (2000) (Abstract).
91. Pinto LA, Edwards J, Castle PE et al.: Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J. Infect. Dis. 188, 338 (2003).
92. MacDonald KS, Kimani J, Dunand VA et al.: Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus Type 1 infection. J. Infect. Dis. 181, 1589 (2000).
93. Kaslow RA, Carrington M, Apple R et al.: Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2, 405-411 (1996).
94. Klein MR, Keet IPM, D'Amaro J et al.: Associations between HLA frequencies and pathogenic features of human immunodeficiency virus Type 1 infection in seroconverters from the Amsterdam cohort of homosexual men. J. Infect. Dis. 169, 1244-1249 (1994).
95. Tang JM, Costello C, Keet IPM et al.: HLA class I homozygosity accelerates disease progression in human immunodeficiency virus Type I infection. AIDS Res. Hum. Retroviruses 15, 317-324 (1999).
96. Zinkernagel RM: Immunology taught by viruses. Science 271, 173-178 (1996).
97. Carrington M, Nelson GW, Martin MP et al.: HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283, 1748-1752 (1999).
98. Carrington M, O'Brien SJ: The influence of HLA genotype on AIDS. Ann. Rev. Med. 54, 535-551 (2003).
99. Zinkernagel RM: Immunity to viruses. In: Fundamental Immunology (3rd edn). Paul WE (Ed.), Raven Press, New York 1211-1250 (1993).
100. Poland GA, Ovsyannikova IG, Johnson KL, Naylor S: The role of mass spectrometry in vaccine development. Vaccine 19, 2692-2700 (2001).
101. Ovsyannikova IG, Johnson KL, Naylor S, Muddiman DC, Poland GA: Naturally processed measles virus peptide eluted from class II HLA-DRB1*03 recognized by T lymphocytes from human blood. Virology 312, 495-506 (2003).
102. Ovsyannikova IG, Johnson KL, Muddiman DC, Vierkant RA, Poland GA: Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides. J. Virol. 78, 42-51 (2004).